FEMY
Femasys Inc.
There isn't enough reported data to score FEMY yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
FEMY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
FEMY's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
FEMY PE Valuation
FEMY has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
FEMY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect FEMY's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
FEMY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$14.40 | +$2.00 |
| Q2 2025 | -$17.20 | -$0.40 |
| Q1 2025 | -$18.20 | -$1.20 |
| Q4 2024 | -$17.00 | +$1.60 |
| Q3 2024 | -$16.40 | +$3.20 |
| Q2 2024 | -$16.80 | +$2.60 |
| Q1 2024 | -$17.00 | +$2.40 |
| Q4 2023 | -$18.60 | +$0.60 |
NVO has the stronger earnings trend. Trailing diluted EPS is down 188% for FEMY versus NVO up 4.9%.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
FEMY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $331.8K | -19% |
| Q1 2026 | $424.9K | +25% |
| Q4 2025 | $813.4K | +40% |
| Q3 2025 | $729.4K | +31% |
| Q2 2025 | $409.3K | +85% |
| Q1 2025 | $341.3K | +26% |
| Q4 2024 | $581.6K | +173% |
| Q3 2024 | $554.9K | +127% |
FEMY has the edge over NVO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1527% | -586 points |
| Q1 2026 | -994% | +606 points |
| Q4 2025 | -568% | +244 points |
| Q3 2025 | -501% | +422 points |
| Q2 2025 | -941% | +1083 points |
| Q1 2025 | -1600% | -323 points |
| Q4 2024 | -812% | +1276 points |
| Q3 2024 | -922% | +748 points |
FEMY's operating margin was −1527% last quarter, down 586 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over FEMY on profitability, with a higher operating margin.
FEMY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.9M | +$501.9K |
| Q1 2026 | -$4.2M | +$639.2K |
| Q4 2025 | -$4.3M | +$856.3K |
| Q3 2025 | -$5.6M | +$300.9K |
| Q2 2025 | -$4.4M | +$62.1K |
| Q1 2025 | -$4.9M | -$229.1K |
| Q4 2024 | -$5.2M | -$2.1M |
| Q3 2024 | -$5.9M | -$3M |
FEMY has burned cash in almost every quarter: −$18M over the past year, against −$20M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over FEMY on cash generation, producing positive trailing cash flow while its opponent burns cash.
FEMY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -14% | -548K shares |
| 1 year | +167% | +2.1M shares |
| 3 years | +468% | +2.8M shares |
| 5 years | +637% | +2.9M shares |
FEMY has 3M diluted shares, up 167% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | $161,761 |
| Q4 2024 | $30,093 |
| Q3 2024 | — |
| Q2 2024 | $6,593 |
| Q1 2024 | $24,067 |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over FEMY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
FEMY Net Leverage
FEMY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
FEMY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.7 | Oversold |
| Stochastic | 4.5 | Oversold |
FEMY's weekly RSI is 29 (oversold) and its Stochastic is 5 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
FEMY PE vs Healthcare Sector
FEMY has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
FEMY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.73 | 19% below |
| 20 week MA | $2.55 | 45% below |
| 50 week MA | $7.09 | 80% below |
| 100 week MA | $13.3 | 89% below |
| 200 week MA | $17.3 | 92% below |
FEMY is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over FEMY on trend strength, trading above more of its moving averages.
FEMY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $240.0 | $91.6 | -62% |
| 2022 | $91.6 | $18.6 | -80% |
| 2023 | $18.6 | $19.5 | +4.8% |
| 2024 | $19.5 | $22.6 | +16% |
| 2025 | $22.6 | $14.2 | -37% |
| 2026 YTD | $14.2 | $1.40 | -90% |
FEMY has finished lower in three of the last five years. It's down 90% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over FEMY on returns for 2026, with the stronger performance.